AIDS Healthcare Foundation Supports Bipartisan SUSTAIN 340B Act to Strengthen and Protect Federal Drug Discount Program
AIDS Healthcare Foundation (AHF) has welcomed the introduction of draft bipartisan legislation in the U.S. Senate aimed at addressing ongoing challenges facing the federal 340B Drug Pricing Program. The proposed legislation, known as the SUSTAIN 340B Act, seeks to strengthen protections for healthcare organizations that rely on discounted prescription medicines to expand access to care for underserved communities.
AHF, one of the largest HIV/AIDS healthcare organizations in the world, said the draft legislation could provide an important framework for protecting the 340B program and the safety-net providers that depend on it. The organization emphasized that the program plays a critical role in helping nonprofit healthcare providers deliver services to patients who may otherwise face significant barriers to medical treatment.
The draft bill was released by a bipartisan group of six U.S. senators and addresses several areas of concern surrounding the administration and use of 340B discounts. These include limitations on the size and scope of the program, restrictions affecting participating healthcare providers, delays involving the payment of discounts, and reimbursement practices that can result in 340B providers receiving lower payments for medicines.
AHF said it is continuing to review the proposed legislation in detail but expressed optimism that the bill could become an important vehicle for strengthening the program.
“While the draft legislation was just released and we are still reviewing the details, we are encouraged by what we have seen so far,” said Tom Myer, General Counsel and Chief of Public Affairs at AHF. “We believe this legislation could provide a meaningful opportunity to protect the 340B program and the communities that depend on the healthcare services it supports. We look forward to engaging with the bipartisan group of senators and working toward legislation that preserves the program’s ability to serve patients.”
340B Program Plays Important Role in Safety-Net Healthcare
Established in 1992, the 340B Drug Pricing Program was created to help certain nonprofit and safety-net healthcare organizations obtain outpatient prescription medicines at discounted prices. The savings generated through the program can help eligible organizations extend healthcare services, reach more patients, and support programs designed to address significant unmet medical needs.
Eligible participants can include rural hospitals, community health centers, HIV/AIDS clinics, and other healthcare organizations that serve vulnerable populations.
The program is particularly important for organizations that operate in communities where patients may face financial, geographic, or other barriers to accessing care. By reducing the cost of qualifying prescription medicines, the program can provide participating providers with additional resources to invest in healthcare services.
For organizations treating people living with HIV, the program can be particularly relevant because HIV care frequently requires ongoing access to prescription therapies and comprehensive clinical services.
AHF has long been involved in discussions surrounding the 340B program and has advocated for maintaining access to discounted medicines for safety-net providers. The organization views the program as an important component of the broader healthcare infrastructure serving low-income and underserved populations.
SUSTAIN 340B Act Addresses Multiple Areas of Concern
According to AHF, the proposed SUSTAIN 340B Act addresses several issues that have emerged as significant points of debate surrounding the 340B program.
One area involves the size and scope of the program. AHF believes protections are needed to ensure that eligible healthcare organizations can continue to participate and benefit from the program in a manner consistent with its original purpose.
Another area involves provider access to 340B discounts. Restrictions on how participating organizations can obtain discounted medicines have become a significant issue in discussions surrounding the program. AHF supports policies that would help ensure eligible providers can continue accessing the discounts necessary to support patient services.
The proposed legislation also addresses delays in payments associated with 340B discounts. Timely access to savings can be important for healthcare organizations operating with limited financial resources, particularly those serving populations with complex medical and social needs.
A further issue addressed by the legislation concerns reimbursement practices. AHF has raised concerns about situations in which insurance companies or other entities may reimburse 340B-participating providers at different rates for medicines. The organization argues that such practices can reduce the financial benefits intended to support safety-net healthcare providers.
Together, these provisions could have implications for the ability of participating organizations to use 340B savings to support patient services.
Potential Impact on Underserved Communities
The debate surrounding the 340B program extends beyond pharmaceutical pricing and reimbursement. For participating organizations, the financial resources generated through the program can contribute to a broader range of healthcare services.
Safety-net providers frequently serve patients who have limited access to healthcare because of income, geography, insurance status, or other circumstances. Many of these organizations provide services that extend beyond the dispensing of medicines, including clinical care, patient education, disease management, prevention programs, and community outreach.
AHF believes maintaining the financial stability of these organizations is important to ensuring that patients continue to have access to comprehensive care.
For HIV/AIDS providers, for example, resources associated with 340B participation can support programs designed to improve treatment access and patient engagement. Effective HIV care often requires regular medical appointments, laboratory monitoring, medication management, adherence support, and other services.
By helping eligible organizations manage medication costs, the 340B program can contribute to their ability to maintain and expand these services.
Bipartisan Interest in 340B Policy
The introduction of the SUSTAIN 340B Act by senators from both political parties reflects the continued national attention surrounding the future of the program.
The 340B program has been the subject of extensive policy discussions involving healthcare providers, pharmaceutical manufacturers, insurers, pharmacy benefit managers, policymakers, and patient advocacy organizations.
Stakeholders have expressed different views about how the program should operate and how its benefits should be distributed. While participating providers and patient advocates emphasize the importance of maintaining affordable access to medicines and supporting safety-net services, other stakeholders have raised questions about program administration, transparency, and the use of 340B savings.
The proposed legislation enters this broader policy debate by seeking to establish additional protections and clarify several aspects of the program.
AHF said it plans to work with lawmakers as the legislative process develops.
AHF Continues Advocacy for Patient Access
AHF’s support for the draft legislation is consistent with the organization’s broader focus on healthcare access and advocacy.
The organization provides medical care, services, and advocacy programs for people living with HIV and works on healthcare policy issues that it believes affect underserved populations.
AHF currently provides healthcare and advocacy services to more than 3.2 million individuals across 50 countries, including the United States and regions throughout Africa, Latin America and the Caribbean, the Asia-Pacific region, and Eastern Europe.
The organization combines direct healthcare delivery with public policy advocacy, seeking to influence policies that affect access to medicines and healthcare services.
AHF said its involvement in the 340B discussion is driven by its view that the program is an important resource for nonprofit providers serving vulnerable populations.
Looking Ahead to the Legislative Process
Although AHF has expressed support for the draft SUSTAIN 340B Act, the organization emphasized that the legislation is still being reviewed and that its provisions will require further examination.
Draft legislation can undergo significant changes as lawmakers consider feedback from healthcare providers, patient organizations, pharmaceutical companies, insurers, and other stakeholders.
The eventual impact of the legislation will depend on its final language, congressional consideration, and whether it ultimately becomes law.
For now, AHF said it intends to engage with the bipartisan Senate group responsible for the proposal and contribute to discussions about how the 340B program can be protected and strengthened.
The organization believes that maintaining the program’s core purpose should remain central to the policy discussion: enabling eligible healthcare providers to use prescription drug savings to support patients and expand services.
Importance of Maintaining the 340B Safety Net
The discussion around the SUSTAIN 340B Act comes at a time when healthcare organizations continue to face pressure to provide high-quality services while managing rising operational and treatment costs.
For safety-net providers, prescription drug discounts can represent an important component of their financial resources. Any changes that reduce access to those discounts could potentially affect the services providers are able to offer, while policies that preserve or strengthen the program could help participating organizations continue serving their communities.
AHF maintains that the interests of patients and safety-net healthcare providers should remain at the center of future 340B policy decisions.
The organization welcomed the bipartisan nature of the proposed legislation and said it looks forward to working with policymakers as the bill moves through the legislative process.
As Congress considers the SUSTAIN 340B Act, the future structure and administration of the 340B program will remain an important issue for healthcare providers, patients, pharmaceutical stakeholders, and policymakers. For organizations such as AHF, the central priority is ensuring that the resources generated through the program continue to contribute to accessible, high-quality healthcare for underserved populations.
The introduction of the SUSTAIN 340B Act therefore represents another significant step in the ongoing national conversation over how the 340B program should operate and how its benefits can best support the patients and communities it was established to serve.